Implants for regenerative medicine
Endogenous cartilage cell implants are used for the treatment of extensive cartilage injuries of the knee joint with very good clinical results.
Together with physicians from the Berufsgenossenschaftliche Unfallklinik Tübingen, a leading therapy procedure in Europe was developed to market readiness and licensed and marketed by TETEC AG, which was founded by the NMI in 2000.
Other cell-based drugs, so-called ATMPs for regenerative medicine, such as injectable intervertebral discs and nerve guidance splints, are in the approval or preclinical development phase. Novel biomaterials play a key role in this. Together with Cellendes GmbH, founded in 2009, the NMI has developed intelligent biomaterials that represent a success factor for new regenerative treatment methods.